Abstract
Background: FGFR inhibition has been proposed as treatment for dedifferentiated liposarcoma (DDLPS) with amplified FRS2, but we previously only demonstrated transient cytostatic effects when treating FRS2-amplified DDLPS cells with NVP-BGJ398. Methods: Effects of the more potent FGFR inhibitor LY2874455 were investigated in three DDLPS cell lines by measuring effects on cell growth and apoptosis in vitro and also testing efficacy in vivo. Genome, transcriptome and protein analyses were performed to characterize the signaling components in the FGFR pathway. Results: LY2874455 induced a stronger, longer-lasting growth inhibitory effect and moderate level of apoptosis for two cell lines. The third cell line, did not respond to FGFR inhibition, suggesting that FRS2 amplification alone is not sufficient to predict response. Importantly, efficacy of LY2874455 was confirmed in vivo, using an independent FRS2-amplified DDLPS xenograft model. Expression of FRS2 was similar in the responding and non-responding cell lines and we could not find any major difference in downstream FGFR signaling. The only FGF expressed by unstimulated non-responding cells was the intracellular ligand FGF11, whereas the responding cell lines expressed extrace...Continue Reading
References
Dec 7, 2000·Biochemistry·J WescheS Olsnes
Jun 22, 2001·Gene·M SleemanJ G Murison
May 3, 2005·Cytokine & Growth Factor Reviews·V P EswarakumarJ Schlessinger
Jun 11, 2009·Current Cancer Drug Targets·M Korc, R E Friesel
Jul 6, 2010·Nature Genetics·Jordi BarretinaSamuel Singer
Aug 12, 2010·Cancer Research·Ensar HalilovicNeal Rosen
Nov 17, 2010·Cellular and Molecular Life Sciences : CMLS·Beat Trueb
Jun 30, 2011·The Biochemical Journal·Jørgen WescheEllen Margrethe Haugsten
Jun 30, 2011·Cancer·Stine H KresseOla Myklebost
Jul 28, 2011·Genes, Chromosomes & Cancer·Xiaoke WangAndre M Oliveira
Sep 9, 2011·Molecular Cancer Therapeutics·Genshi ZhaoDenis J McCann
Sep 23, 2011·Journal of Medicinal Chemistry·Vito GuagnanoDiana Graus Porta
Feb 14, 2012·Pharmaceutical Statistics·J L Sebaugh
Sep 25, 2012·Cancer Discovery·Vito GuagnanoDiana Graus-Porta
Oct 6, 2012·Clinical Sarcoma Research·Zachary BurninghamJoshua D Schiffman
Feb 9, 2013·Cancer Research·Keqiang ZhangYun Yen
May 27, 2014·Stem Cells and Development·Magne SkårnOla Myklebost
Nov 5, 2014·Molecular Cancer Research : MCR·Leo Y LuoWilliam C Hahn
Mar 18, 2015·Cancer Discovery·Margit HagelTimothy Guzi
Dec 9, 2015·Oncotarget·Deepika KanojiaH Phillip Koeffler
Jul 14, 2016·Oncotarget·Robert HanesOla Myklebost
Sep 13, 2016·PloS One·Daichao WuYongheng Chen
Jan 19, 2017·Oncotarget·Naofumi AsanoHitoshi Ichikawa
Jun 8, 2017·Targeted Oncology·Michael MichaelJeanne Tie
Citations
Oct 5, 2019·Cells·Klaus Holzmann, Brigitte Marian
Sep 29, 2019·Expert Opinion on Investigational Drugs·Dan WangYi Zhang
Oct 24, 2020·Cancers·Bérengère Dadone-MontaudiéLaurence Bianchini
Apr 4, 2021·Cancers·Yijun WangLimin Xia
Apr 25, 2021·Molecular Biology Reports·Jun LuDaniel Wong
Jun 19, 2021·Nature Communications·Matteo A MolèMagdalena Zernicka-Goetz
Jul 3, 2021·Cells·Andrea NapolitanoPaul H Huang
Aug 18, 2021·Scientific Reports·Fariba Dehghanian, Shahryar Alavi